Description

Strain Information

Former Names FVB-Tg(MMTV-Erbb2)1Led/J    (Changed: 25-JUL-06 ) Type Coisogenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Mating System Homozygote x Homozygote         (Female x Male)   01-MAR-06 Species laboratory mouse Generation F?+N1F13 (31-DEC-08) Generation Definitions   Donating Investigator Dr. Philip Leder,   Harvard Medical School

Description
These transgenic mice express the activated rat Erbb2 (c-neu) oncogene under the direction of the mouse mammary tumor virus promoter. The activated, or transforming, version of the rat Erbb2 (c-neu) oncogene has a valine to glutamic acid substitution at acid 664, (Val⁶⁶⁴ to Glu⁶⁶⁴). Non-uniform and random transgene expression is detected by RNase protection assay in mammary gland epithelium from hemizygous mice. Tumor formation is multifocal, stochastic and matches the expression pattern of the transgene. While no transgene expression is detected at 5 and 8 weeks of age in normal mammary gland tissue, it is detected in adenocarcinomas from older (23 week old) mice. The donating investigator indicates that 50% of transgenic mice derived from the TG.NK founder line, develop tumors within 6-12 months of age. Mice that are homozygous for the targeted mutation are viable, fertile and normal in size.

Development
A transgenic construct containing sequence encoding the mouse mammary tumor virus LTR promoter, 4.6kb of sequence encoding the activated rat Erbb2 (c-neu) oncogene, and SV40 polyadenylation site sequence was microinjected into fertilized FVB/N eggs.

Control Information

	Control
	001800 FVB/NJ
Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Erbb2

007962	B6.FVB-Tg(MMTV-neu/OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J
010577	B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002376	FVB/N-Tg(MMTVneu)202Mul/J

View Strains carrying other alleles of Erbb2     (3 strains)

Strains carrying other alleles of MMTV

004997	B6.Cg-Tg(MMTV-TGFBR2)7Hlm/J
002618	B6.Cg-Tg(MMTVtTA)1Mam/J
007962	B6.FVB-Tg(MMTV-neu/OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J
002375	B6;D2-Tg(MMTVTGFB1)46Hlm/J
010576	B6;SJL-Tg(MMTV-rtTA)4-1Jek/J
002459	B6D2-Tg(MMTVTGFA)254Rjc/J
002373	B6D2-Tg(MMTVTGFA)29Rjc/J
002870	B6SJL-Tg(Wnt1)1Hev/J
004363	FVB.Cg-Tg(MMTV-vHaras)SH1Led/J
002953	FVB.Cg-Tg(MMTVTGFA)254Rjc/J
002934	FVB.Cg-Tg(Wnt1)1Hev/J
002437	FVB/N-Tg(MMTV-Notch4)3Rnc/J
002374	FVB/N-Tg(MMTV-PyVT)634Mul/J
002376	FVB/N-Tg(MMTVneu)202Mul/J
002933	FVB/NJ-Tg(MMTVTGFB1)46Hlm/J
003690	STOCK Tg(MMTV-Cdc37)1Stp/J
003337	STOCK Tg(MMTV-PIP)1Shu/J
003551	STOCK Tg(MMTV-cre)1Mam/J
003553	STOCK Tg(MMTV-cre)4Mam/J

View Strains carrying other alleles of MMTV     (19 strains)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI

      assigned by genotype

Tg(MMTV-Erbb2)NK1Mul/0

        involves: FVB/N

• tumorigenesis
• mammary adenocarcinoma
  • female mice exhibit diffuse, polyclonal tumor masses   (MGI Ref ID J:48632)
  • tumor morphogenesis corresponds to transgene expression   (MGI Ref ID J:48632)
  • tumors are more sparsely distributed than in other lines of the transgene   (MGI Ref ID J:48632)

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Tg(MMTV-Erbb2)NK1Mul/0

        involves: 129P2/OlaHsd * C57BL/6 * FVB/N

• tumorigenesis
• increased mammary gland tumor incidence   (MGI Ref ID J:76653)
• increased tumor latency
  • mice display 50% tumor incidence at 52 weeks of age compared to 25 weeks of age in mice on an FVB/N background   (MGI Ref ID J:76653)
  • mice ovariectomized at 18-20 days of age, but not those ovariectomized at 16-20 weeks of age, display a further delay in tumor onset (50% incidence at 62 weeks of age)   (MGI Ref ID J:76653)
  • breeding females accelerates tumor development (50% incidence at 32 weeks of age)   (MGI Ref ID J:76653)
• reproductive system phenotype
• *normal* reproductive system phenotype
  • unlike in previous reports, mammary gland ductal structure is not different from controls prior to the onset of tumor formation   (MGI Ref ID J:76653)

Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

        involves: 129 * C57BL/6 * FVB/N

• tumorigenesis
• mammary adenocarcinoma
  • all female virgin mice develop cancer tumors in the breast by 45 weeks of age   (MGI Ref ID J:117336)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Cancer Research
Increased Tumor Incidence
      Mammary Gland Tumors

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol		Tg(MMTV-Erbb2)NK1Mul
Allele Name		transgene insertion NK1, William Muller
Allele Type		Transgenic (random, expressed)
Common Name(s)		HER-2/neu; MMTV c-neu; MMTV-Tg.NK; MMTV-erbB2; MMTV-neu; TG.NK; Tg(MMTV-Erbb2)1Led;
Mutation Made By		Dr. Philip Leder,   Harvard Medical School
Strain of Origin		FVB/N
Expressed Gene		Erbb2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), rat
Promoter		MMTV, Mouse Mammary Tumor Virus, MMTV
General Note		Tumor formation in transgenic mice is multifocal, stochastic, and matches the expression pattern of the transgene. While no transgene expression is detected at 5 and 8 weeks of age in normal mammary gland tissue, expression is detected in adenocarcinomasfrom older (23 week old) mice. 50% of transgenic mice derived from this founder line develop tumors within 6-12 months of age.
Molecular Note		This transgene contains the MMTV (mouse mammary tumor virus) LTR promoter, a 4.6 kb cDNA from the rat Erbb2 (avian erythroblastosis B2) oncogene, and an SV40 polyadenylation site sequence. The activated form of the rat gene is used in this construct, which differs from the wild-type allele by a point mutation, Val664Glu. Non-uniform and random transgene expression is detected by RNase protection assay in mammary gland epithelium from hemizygous transgenic mice. Six transgenic lines were produced (NA, NB,NF, NK, NL and NM). [MGI Ref ID J:48632]

Genotyping

Genotyping Information

Genotyping Protocols

Tg(MMTV-Erbb2)NK1Mul, QPCR
Tg(MMTV-Erbb2)NK1Mul, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Muller WJ; Sinn E; Pattengale PK; Wallace R; Leder P. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54(1):105-15. [PubMed: 2898299]  [MGI Ref ID J:48632]

Additional References

Tg(MMTV-Erbb2)NK1Mul related

Bai L; Rohrschneider LR. 2010. s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev 24(17):1882-92. [PubMed: 20810647]  [MGI Ref ID J:163521]

Balboni AL; Hutchinson JA; DeCastro AJ; Cherukuri P; Liby K; Sporn MB; Schwartz GN; Wells WA; Sempere LF; Yu PB; DiRenzo J. 2013. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 73(2):1020-30. [PubMed: 23243027]  [MGI Ref ID J:194364]

Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE. 1998. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18(1):85-92. [PubMed: 9418856]  [MGI Ref ID J:78608]

Bentires-Alj M; Neel BG. 2007. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res 67(6):2420-4. [PubMed: 17347513]  [MGI Ref ID J:120339]

Bienvenu F; Jirawatnotai S; Elias JE; Meyer CA; Mizeracka K; Marson A; Frampton GM; Cole MF; Odom DT; Odajima J; Geng Y; Zagozdzon A; Jecrois M; Young RA; Liu XS; Cepko CL; Gygi SP; Sicinski P. 2010. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 463(7279):374-8. [PubMed: 20090754]  [MGI Ref ID J:156591]

Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX. 2001. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene 20(12):1445-54. [PubMed: 11313888]  [MGI Ref ID J:69223]

Brown NE; Jeselsohn R; Bihani T; Hu MG; Foltopoulou P; Kuperwasser C; Hinds PW. 2012. Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res 72(24):6477-89. [PubMed: 23041550]  [MGI Ref ID J:193650]

Bulavin DV; Phillips C; Nannenga B; Timofeev O; Donehower LA; Anderson CW; Appella E; Fornace AJ Jr. 2004. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36(4):343-50. [PubMed: 14991053]  [MGI Ref ID J:121570]

Cameron HL; Foster WG. 2009. Developmental and lactational exposure to dieldrin alters mammary tumorigenesis in Her2/neu transgenic mice. PLoS ONE 4(1):e4303. [PubMed: 19173004]  [MGI Ref ID J:144833]

Cardiff RD; Anver MR; Gusterson BA; Hennighausen L; Jensen RA; Merino MJ; Rehm S; Russo J; Tavassoli FA; Wakefield LM; Ward JM; Green JE. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [see comments] Oncogene 19(8):968-88. [PubMed: 10713680]  [MGI Ref ID J:61035]

Cardiff RD; Sinn E; Muller W; Leder P. 1991. Transgenic oncogene mice. Tumor phenotype predicts genotype. Am J Pathol 139(3):495-501. [PubMed: 1887859]  [MGI Ref ID J:72086]

Chen DY; Lee Y; Van Tine BA; Searleman AC; Westergard TD; Liu H; Tu HC; Takeda S; Dong Y; Piwnica-Worms DR; Oh KJ; Korsmeyer SJ; Hermone A; Gussio R; Shoemaker RH; Cheng EH; Hsieh JJ. 2012. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res 72(3):736-46. [PubMed: 22166309]  [MGI Ref ID J:181107]

Choi YJ; Li X; Hydbring P; Sanda T; Stefano J; Christie AL; Signoretti S; Look AT; Kung AL; von Boehmer H; Sicinski P. 2012. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22(4):438-51. [PubMed: 23079655]  [MGI Ref ID J:192032]

Dillon RL; Brown ST; Ling C; Shioda T; Muller WJ. 2007. An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer. Mol Cell Biol 27(24):8648-57. [PubMed: 17938205]  [MGI Ref ID J:128960]

Fantozzi A; Christofori G. 2006. Mouse models of breast cancer metastasis. Breast Cancer Res 8(4):212. [PubMed: 16887003]  [MGI Ref ID J:116013]

Gabai VL; Meng L; Kim G; Mills TA; Benjamin IJ; Sherman MY. 2012. Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. Mol Cell Biol 32(5):929-40. [PubMed: 22215620]  [MGI Ref ID J:183719]

Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS. 2002. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res 62(10):2798-805. [PubMed: 12019156]  [MGI Ref ID J:76653]

Jeselsohn R; Brown NE; Arendt L; Klebba I; Hu MG; Kuperwasser C; Hinds PW. 2010. Cyclin D1 Kinase Activity Is Required for the Self-Renewal of Mammary Stem and Progenitor Cells that Are Targets of MMTV-ErbB2 Tumorigenesis. Cancer Cell 17(1):65-76. [PubMed: 20129248]  [MGI Ref ID J:156929]

Ju X; Katiyar S; Wang C; Liu M; Jiao X; Li S; Zhou J; Turner J; Lisanti MP; Russell RG; Mueller SC; Ojeifo J; Chen WS; Hay N; Pestell RG. 2007. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 104(18):7438-43. [PubMed: 17460049]  [MGI Ref ID J:121297]

Koyama H; Kobayashi N; Harada M; Takeoka M; Kawai Y; Sano K; Fujimori M; Amano J; Ohhashi T; Kannagi R; Kimata K; Taniguchi S; Itano N. 2008. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment. Am J Pathol 172(1):179-93. [PubMed: 18079437]  [MGI Ref ID J:130531]

Landis MW; Pawlyk BS; Li T; Sicinski P; Hinds PW. 2006. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9(1):13-22. [PubMed: 16413468]  [MGI Ref ID J:105045]

Law M; Forrester E; Chytil A; Corsino P; Green G; Davis B; Rowe T; Law B. 2006. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 66(2):1070-80. [PubMed: 16424043]  [MGI Ref ID J:106547]

Lehembre F; Yilmaz M; Wicki A; Schomber T; Strittmatter K; Ziegler D; Kren A; Went P; Derksen PW; Berns A; Jonkers J; Christofori G. 2008. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J 27(19):2603-15. [PubMed: 18772882]  [MGI Ref ID J:141157]

Leng X; Ding T; Lin H; Wang Y; Hu L; Hu J; Feig B; Zhang W; Pusztai L; Symmans WF; Wu Y; Arlinghaus RB. 2009. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 69(22):8579-84. [PubMed: 19887608]  [MGI Ref ID J:154442]

Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH. 2008. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 98(8):1380-8. [PubMed: 18362934]  [MGI Ref ID J:137272]

Li Y; Zhang Y; Hill J; Shen Q; Kim HT; Xu X; Hilsenbeck SG; Bissonnette RP; Lamph WW; Brown PH. 2007. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13(20):6224-31. [PubMed: 17947490]  [MGI Ref ID J:131196]

Luijten M; Thomsen AR; van den Berg JA; Wester PW; Verhoef A; Nagelkerke NJ; Adlercreutz H; van Kranen HJ; Piersma AH; Sorensen IK; Rao GN; van Kreijl CF. 2004. Effects of soy-derived isoflavones and a high-fat diet on spontaneous mammary tumor development in Tg.NK (MMTV/c-neu) mice. Nutr Cancer 50(1):46-54. [PubMed: 15572297]  [MGI Ref ID J:95478]

Luijten M; Verhoef A; Dormans JA; Beems RB; Cremers HW; Nagelkerke NJ; Adlercreutz H; Penalvo JL; Piersma AH. 2007. Modulation of mammary tumor development in Tg.NK (MMTV/c-neu) mice by dietary fatty acids and life stage-specific exposure to phytoestrogens. Reprod Toxicol 23(3):407-13. [PubMed: 17229545]  [MGI Ref ID J:121510]

Maroulakou IG; Oemler W; Naber SP; Tsichlis PN. 2007. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67(1):167-77. [PubMed: 17210696]  [MGI Ref ID J:117336]

Meyer DS; Brinkhaus H; Muller U; Muller M; Cardiff RD; Bentires-Alj M. 2011. Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors. Cancer Res 71(13):4344-51. [PubMed: 21482677]  [MGI Ref ID J:173655]

Mortensen A; Kramer F; Lindecrona RH; Sorensen IK. 2004. Investigation of the effect of lignans on murine mammary gland differentiation in TG.NK mice. Asia Pac J Clin Nutr 13(Suppl):S172. [PubMed: 15294749]  [MGI Ref ID J:92112]

Pradeep CR; Kostler WJ; Lauriola M; Granit RZ; Zhang F; Jacob-Hirsch J; Rechavi G; Nair HB; Hennessy BT; Gonzalez-Angulo AM; Tekmal RR; Ben-Porath I; Mills GB; Domany E; Yarden Y. 2012. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 31(7):907-17. [PubMed: 21743488]  [MGI Ref ID J:181067]

Quan L; Dittmar A; Zhou Y; Hutson A; Stassen AP; Demant P. 2012. Susceptibility loci affecting ERBB2/neu-induced mammary tumorigenesis in mice. Genes Chromosomes Cancer 51(7):631-43. [PubMed: 22419448]  [MGI Ref ID J:185943]

Rajkumar L; Kittrell FS; Guzman RC; Brown PH; Nandi S; Medina D. 2007. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res 9(1):R12. [PubMed: 17257424]  [MGI Ref ID J:121486]

Rao GN; Ney E; Herbert RA. 1999. Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene Breast Cancer Res Treat 58(3):241-54. [PubMed: 10718486]  [MGI Ref ID J:61198]

Rao GN; Ney E; Herbert RA. 2000. Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat 64(3):287-96. [PubMed: 11200779]  [MGI Ref ID J:67457]

Rao GN; Ney E; Herbert RA. 1997. Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue. Breast Cancer Res Treat 45(2):149-58. [PubMed: 9342440]  [MGI Ref ID J:43631]

Ray D; Terao Y; Fuhrken PG; Ma ZQ; DeMayo FJ; Christov K; Heerema NA; Franks R; Tsai SY; Papoutsakis ET; Kiyokawa H. 2007. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res 67(3):984-91. [PubMed: 17283130]  [MGI Ref ID J:118218]

Ray D; Terao Y; Nimbalkar D; Hirai H; Osmundson EC; Zou X; Franks R; Christov K; Kiyokawa H. 2007. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 67(14):6605-11. [PubMed: 17638870]  [MGI Ref ID J:123144]

Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE. 2012. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 104(6):476-87. [PubMed: 22302033]  [MGI Ref ID J:184943]

Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM. 2012. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 209(2):275-89. [PubMed: 22271573]  [MGI Ref ID J:181875]

Shen Q; Brown PH. 2005. Transgenic mouse models for the prevention of breast cancer. Mutat Res 576(1-2):93-110. [PubMed: 15888345]  [MGI Ref ID J:100623]

Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH. 2009. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107-13. [PubMed: 19141783]  [MGI Ref ID J:144996]

Strumane K; Rygiel T; van der Valk M; Collard JG. 2009. Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice. J Cancer Res Clin Oncol 135(1):69-80. [PubMed: 18592271]  [MGI Ref ID J:142164]

Taverna D; Crowley D; Connolly M; Bronson RT; Hynes RO. 2005. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 65(22):10324-9. [PubMed: 16288021]  [MGI Ref ID J:103405]

Tekmal RR; Nair HB; Perla RP; Kirma N. 2007. HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis. J Steroid Biochem Mol Biol 106(1-5):111-8. [PubMed: 17604617]  [MGI Ref ID J:143149]

Thomsen AR; Mortensen A; Breinholt VM; Lindecrona RH; Penalvo JL; Sorensen IK. 2005. Influence of Prevastein, an isoflavone-rich soy product, on mammary gland development and tumorigenesis in Tg.NK (MMTV/c-neu) mice. Nutr Cancer 52(2):176-88. [PubMed: 16201849]  [MGI Ref ID J:104183]

Tilli MT; Furth PA. 2003. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 5(4):202-5. [PubMed: 12817992]  [MGI Ref ID J:84503]

Wall EM; Milne K; Martin ML; Watson PH; Theiss P; Nelson BH. 2007. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 67(13):6442-50. [PubMed: 17616705]  [MGI Ref ID J:122846]

Wen HC; Avivar-Valderas A; Sosa MS; Girnius N; Farias EF; Davis RJ; Aguirre-Ghiso JA. 2011. p38alpha Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis. Sci Signal 4(174):ra34. [PubMed: 21610252]  [MGI Ref ID J:185994]

Yang C; Hayashida T; Forster N; Li C; Shen D; Maheswaran S; Chen L; Anderson KS; Ellisen LW; Sgroi D; Schmidt EV. 2011. The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res 71(3):937-45. [PubMed: 21127199]  [MGI Ref ID J:169326]

Yu Q; Sicinska E; Geng Y; Ahnstrom M; Zagozdzon A; Kong Y; Gardner H; Kiyokawa H; Harris LN; Stal O; Sicinski P. 2006. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9(1):23-32. [PubMed: 16413469]  [MGI Ref ID J:105043]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX12

Colony Maintenance

Breeding & Husbandry	The resulting transgenic mice were bred to homozygosity, and the genotypes confirmed by quantitative PCR.
Mating System	Homozygote x Homozygote         (Female x Male)   01-MAR-06
Diet Information	LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

General Supply Notes

• Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

	Control
	001800 FVB/NJ
Considerations for Choosing Controls
Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering Information
JAX^® Mice
Surgical and Preconditioning Services
JAX^® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Notice to customers in Canada.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.